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Abstract 262 1	
 2	
Cytokine dysregulation is believed to play a key role in the remodeling of the immune 3	
system at older age, with evidence pointing to an inability to fine-control systemic 4	
inflammation, which seems to be a marker of unsuccessful aging. This reshaping of 5	
cytokine expression pattern, with a progressive tendency toward a pro-inflammatory 6	
phenotype has been called ‘inflamm-aging’. Despite research there is no clear 7	
understanding about the causes of ‘inflamm-aging’ that underpin most major age-8	
related diseases including atherosclerosis, diabetes, Alzheimer’s disease, rheumatoid 9	
arthritis, cancer and aging itself.  10	
 11	
While inflammation is part of the normal repair response for healing, and essential in 12	
keeping us safe from bacterial and viral infections and noxious environmental agents, 13	
not all inflammation is good. When inflammation becomes prolonged and persists, it 14	
can become damaging and destructive. Several common molecular pathways have 15	
been identified that are associated with both aging and low-grade inflammation.  16	
 17	
The age-related change in redox balance, the increase in age-related senescent cells 18	
and SASP and the decline in effective autophagy that can trigger the inflammasome, 19	
suggest that it may be possible to delay age-related diseases and aging itself by 20	
suppressing pro-inflammatory molecular mechanisms or improving the timely 21	
resolution of inflammation. Conversely there may be learning from molecular or 22	
genetic pathways from long-lived cohorts who exemplify good quality aging.  23	
 24	
Here we will discuss some of the current ideas and highlight molecular pathways that 25	
appear to contribute to the immune imbalance and the cytokine dysregulation, which 26	
is associated with ‘inflammageing’ or parainflammation. Evidence of these findings 27	
will be drawn from research in cardiovascular disease and rheumatoid arthritis, two 28	
age-related diseases 29	
 30	
 31	
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1. Introduction  1	
The inflammatory response must be tightly regulated to ensure effective immune 2	
protection. It is a dynamic network that is continuously remodelling throughout each 3	
person’s life as a result of the interaction between our genes, life-styles and 4	
environments (1-3). Infections and tissue damage from the external environment and 5	
our personal internal response to stress can act as triggers to initiate the inflammatory 6	
defense response. While inflammation is part of the normal repair response for 7	
healing, and essential in keeping us safe from bacterial and viral infections and 8	
noxious environmental agents, not all inflammation is good. When inflammation 9	
becomes prolonged and persists, it can become damaging and destructive (4). It is 10	
essential that inflammation is tailored to the initiating stress and resolves in a timely 11	
and controlled way, to avoid pathology associated with chronicity. 12	
 13	
The cytokine network is a highly complex system of immune molecular messengers, 14	
with multiple layers of activation and control mediated through soluble receptors, 15	
receptor antagonists, diverse serum mediators as well as gene polymorphisms (5). 16	
Proteomic methods measuring cytokine production and expression have demonstrated 17	
further layers of complexity and control in cytokine production and expression 18	
involving long coding RNAs, siRNAs and miRNAs, which make for challenging 19	
interpretation of cytokine production and control in the inflammatory process (6). 20	
Many cytokines are able to act in more than one-way or paradoxically at different 21	
times, and many act in feedback loops with the ability to auto-control their own 22	
production (7). Cytokine expression is also influenced by local cellular 23	
microenvironments, suggesting that multiple pathways exist to achieve homeostatic 24	
immunologic control and effectiveness, or conversely accentuation of chronic 25	
immune activation. However what seems clear is that mirroring other body systems, 26	
the homeostatic control, titration and modulation of immune responsiveness becomes 27	
more fragile and less tightly focused with increasing age. This loosening of the 28	
cytokine balance between the pro-inflammatory and anti-inflammatory control or 29	
resolving mechanisms, or inflamm-aging (8,9), is a characteristic feature of both 30	
aging and aging-related diseases. This kind of inflammation is similar to that 31	
originally described as ‘parainflammation’ as described by Medzhitov (10).  32	
 33	
Today there is increasing recognition that inflammation is a common molecular 34	
pathway that underlies in part, the pathogenesis of diverse human diseases ranging 35	
from infection, to immune-mediated disorders, cardiovascular pathology, diabetes, 36	
metabolic syndrome, neurodegeneration and cancer, to aging itself (4,11,12). 37	
Although there is no exact understanding about the causes of ‘inflamm-ageing’, a 38	
common finding seems to involve a dysregulation of the cytokine network and its 39	
homeostasis. Several common molecular pathways have been identified that seem to 40	
be associated with both aging and low-grade inflammation. Excess oxidative stress 41	
and DNA damage trigger the inflammasome, stimulating NF-κB and the IL-1β-42	
mediated inflammatory cascade. Autophagy, the cell machinery process that removes 43	
damaged proteins and large aggregates, is also slowed up at older age and in age-44	
related disease, causing damaged material to accumulate and reduce cellular 45	
efficiency. Senescent cells increase with age and in age-related diseases, and the 46	
associated secretome or senescence-associated secretory phenotype (SASP) produces 47	
a self-perpetuating intracellular signaling loop and inflammatory cascade involving 48	
the NF-κB, IL-1α, TGF-β, IL-6 pathway, that participates in the pro-inflammatory 49	
milieu. The molecular processes that damp down inflammation include the resolvin 50	
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family of bioactive molecules, which have been much less evaluated in aging or age-1	
related disease, but are important participants in effective and timely inflammation 2	
resolution. 3	
 4	
Here we will discuss some of the current ideas and highlight molecular pathways that 5	
appear to contribute to the immune imbalance and the cytokine dysregulation, which 6	
is associated with ‘inflamm-aging’ or parainflammation. Evidence of these findings 7	
will be drawn from research in several age-related diseases including cardiovascular 8	
and neurodegenerative disease, rheumatoid arthritis and oncological cancers. 9	
 10	
2. The inflammation pathway to resolution  11	
 12	
Inflammation is classically induced when innate cells detect infection or tissue injury. 13	
The pattern-recognition receptors (PRRs) on immune cells sense ‘danger’ from 14	
protein-associated molecular patterns (PAMPs) associated with pathogens, or from 15	
danger-associated molecular patterns (DAMPs) triggered by a wide range of host-16	
derived endogenous stress signals. DAMPs are molecules such as ATP, the cytokine 17	
IL-1a, uric acid and some cytoplasmic and nuclear proteins, which are released from 18	
damaged cells during necrosis and contribute to sterile inflammation (Fig 1). There 19	
have been suggestions that the extended IL-1 cytokine family (IL-1α, IL-1β, IL-18, 20	
IL-33, IL-36α, IL-36β, and IL-36γ) might also act as DAMPs and stimulate necrosis-21	
initiated sterile inflammation, as well as amplify inflammation in response to 22	
infection-associated tissue injury (13).  23	
 24	
Members of the Toll-Like Receptor (TLR) family are the major pattern-recognition 25	
receptors (PRRs). They are expressed on monocytes, macrophages, neutrophils and 26	
dendritic cells, and on some lymphocytes and they respond rapidly to the ‘danger’ 27	
response. The cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways of 28	
arachidonic acid (AA) metabolism (14,15) produce highly pro-inflammatory lipid 29	
mediators responsible for the classical signs of inflammation - redness, heat, pain, 30	
swelling and loss of function, with the aim of removing the injurious and noxious 31	
stimuli. A third pathway involves the cytochrome 450 pathway of arachidonic acid 32	
metabolism and P450 epoxygenases and hydroxylases that produce both 33	
vasoconstrictor and vasodilatory effects in blood vessels and other tissues (Fig 2). The 34	
reactive biolipid molecules synthesized from arachidonic acid (AA) are; the 35	
prostanoids - prostaglandins, (PGs), prostacyclins (PGIs) and thromboxanes (TXs) 36	
produced by the action of cyclooxygenase 1 and 2 (COX 1 & 2 ); the leukotrienes 37	
(LTs), hydroxyeicosatetraenoids (HETEs) and lipoxins (LXs) produced by the action 38	
of the 5-12-and 15-lypooxygenase (5/1/15-LOX) enzymes and; the P450 epoxygenase 39	
generates HETEs and depoxyeicosatrienoids (epoxides) (16). Prostaglandins act to 40	
amplify the inflammatory response through enhancing the inflammatory cytokine 41	
cascade, upregulating the innate response to DAMPs and PAMPs, activating subsets 42	
of T helper cells, recruiting macrophages associated with chronic inflammation and 43	
increasing cytokine expression from cytokine inflammatory genes. Additional factors 44	
such as histamine, pro-inflammatory cytokines and chemokines amplify the response 45	
further and make the vascular endothelium increasingly leaky. The increase in 46	
vascular permeability combined with the expression of cellular adhesion molecules 47	
(ie selectins and integrins) allows neutrophils, the first responders, to transmigrate 48	
across post-capillary venules to the sites of injury or microbial invasion. Together this 49	
increases polymorphonuclear (PMN) neutrophil chemotaxis and allows PMNs to 50	
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transmigrate along chemotactic gradients in order to maximize phagocytosis and 1	
killing of pathogens, and deal with the ‘danger’ signal effectively.  2	
 3	
As the acute inflammatory cascade develops to manage the ‘danger’ signal, it is 4	
essential that a controlled resolution commence, so that immune homeostasis returns 5	
in an organized manner. If the inflammatory response does not shut down in a timely 6	
way, the inflammation cascade becomes chronic and smoldering. Lipid mediators 7	
derived from polyunsaturated fatty acids are now recognised to orchestrate the 8	
resolution of inflammation (17). At the peak of inflammation, the eicosanoids that 9	
initiated the inflammation undergo a class-switch so that they become the molecules 10	
that activate resolution, demonstrable through the clinical signs of-removal of 11	
symptoms, relief of pain, restoration of function, regeneration of damaged tissues and 12	
return to health. The so called specialized pro-resolving mediators (SPMs) are key to 13	
resolving inflammation and include lipoxins derived from the 5-lipoxygenase (5-14	
LOX) arm of the arachidonic acid pathway; the E-group of resolvins derived from 15	
dietary-derived eicosapentaenoic acid (EPA); the D-group of resolvins from dietary–16	
derived docosahenaenoic acid (DHA); and protectins (PD), and maresins (MaR) (17-17	
19) (Fig 2). The lipid class-switch starts early in inflammation and is initiated by 18	
lipoxins LXA4 and LXB4, and considered to be produced by platelets when they 19	
begin to aggregate with PMNs at the sites of inflammation (18). 20	
 21	
After class-switching of the lipid molecules has occurred, specialized pro-resolving 22	
mediators are produced. Pro-resolving monocyte-derived macrophages begin to clear 23	
PMNs from the site of injury by a process called efferocytosis that removes apoptotic 24	
neutrophils, microbes and necrotic debris. As resolution progresses, monocytes and 25	
macrophages, change from a pro-inflammatory (M1) to a pro-resolving phenotype 26	
(M2) by genetic and epigenetic reprogramming (20-22). Recent investigations suggest 27	
that SPMs, particularly the D-series resolvins (resolving D1 and resolving D2) and 28	
maresin 1 modulate adaptive immune responses in human peripheral blood 29	
lymphocytes. These lipid mediators reduce cytokine production by activated CD8+ T 30	
cells and CD4+ T helper I (TH1) and TH 17 cells, but do no modulate T cell 31	
inhibitory receptors or reduce their ability to proliferate (23,24). Other reports show 32	
an increase in plasma cell differentiation and antibody production that supports the 33	
involvement of SPMs in the humoral reponse during late stages of inflammation and 34	
pathogen clearance (25). The anti-inflammatory cytokines IL-10, and IL-37 a member 35	
of the IL-1 family, together with TGF-β that is released from monocytes and platelets, 36	
are important contributors to damping down the inflammation. The soluble receptors 37	
TNFR and IL-1R also limit inflammation in acting as decoy receptors, by binding to 38	
and neutralizing their respective cytokines, and inhibiting the biological activity. 39	
Additional anti-inflammatory mechanisms include stress hormones, particularly 40	
corticosteroids and catecholamines and negative regulators such as microRNAs - 41	
MiR-146 and MiR-125 (26).  42	
 43	
The local environment and context also play an important role in the production and 44	
function of SPMs, which have both autocrine and paracrine actions. Inflammation 45	
resolution is likely to depend on prompt class-switching to pro-resolving lipid 46	
mediators, effective apoptosis and efferocytic clearance of inflammatory cells and 47	
debris, timely damping down of pro-inflammatory signals and integrated repair of 48	
collateral damage. An imbalance between pro-inflammatory and pro-resolving 49	
mediators has been linked to a number of chronic inflammatory diseases (27). 50	
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 1	
In normal inflammation SPMs do not compromise host immune competence with 2	
examples of pro-resolving mediators increasing survival from infections in mouse 3	
models (28,29). The common mechanism by which this occurs appears to be through 4	
suppression of the NF-kB activation in a partly PPAR-γ-dependent manner, with 5	
associated downstream signaling and alteration in transcriptomics pathways (30,31). 6	
Dysregulation of pro-resolving mediators has been associated with diseases of 7	
prolonged inflammation in animal models. A maresin mediator (MaR1) has been 8	
shown to have potent anti-inflammatory and pro-resolving actions in a model of 9	
colitis, and attenuated inflammation in vascular smooth muscle and endothelial cells 10	
(32,33). In human studies, the role of SPMs are being explored in chronic 11	
inflammatory diseases such as rheumatoid arthritis (34), in atherosclerosis (27), in 12	
cancer (35) and in Alzheimer’s disease whereas several SPMs promoted neuronal 13	
survival and β-amyloid uptake by microglia in ‘in vitro’ models in Alzheimer’s 14	
disease (36,37). However little is known about the pro-resolving mediators in age-15	
related diseases and aging itself. Studies are needed assess whether pro-resolving 16	
molecules such as E and D-resolvins and maresins decrease or are less effective in 17	
damping down inflammation with increasing age and whether they could contribute to 18	
the pro-inflammatory phenotype associated with aging. Already synthetic analogues 19	
are in process of development and so the design of pharmacological mimetics of 20	
naturally occurring pro-resolving mediators and their receptors offers new potential 21	
targets for drug design and the opportunity to investigate the underpinning molecular 22	
mechanisms of inflammation resolution.  23	
 24	
Could life-style factors play a role in the epidemic of non-communicable and age-25	
related diseases and the associated pro-inflammatory phenotype? Evidence exists that 26	
suggests that the Mediterranean diet which includes olive oil and some omega-3 27	
lipids, can ameliorate rheumatoid arthritis (38), may give some protection from atrial 28	
fibrillation and myocardial infarction (39), and improves diabetic control (40). 29	
Research has also demonstrated a protective role of the Mediterranean diet in 30	
gene/Mediterranean diet interactions for the risk TT allele of the TCF7L2-rs7903146 31	
gene in stroke risk and mortality (41,42). Improving knowledge about how 32	
inflammation shuts down in a timely way is crucial to understanding of how chronic 33	
inflammation contributes to aging and age-related diseases. Further studies are likely 34	
to be needed to advise if dietary modifications with omega-3 lipids or whether 35	
synthetic resolving mimetics are part of the answer.  36	
 37	
3. Triggers of the inflammation pathway 38	
Several common molecular pathways have been identified that seem to be associated 39	
with both aging and low-grade inflammation. These pathways trigger the 40	
inflammasome, stimulating NF-κB and the IL-1β-mediated inflammatory cascade. 41	
 42	
3.1. Age-related redox imbalance  43	
A redox imbalance has been long been associated with aging and led to the 44	
development of the redox stress hypothesis of aging (43). Redox stress is caused by 45	
an imbalance between unregulated and overproduced reactive oxidative species 46	
(ROS) that are produced secondary to mitochondrial energy production, active 47	
immunological phagocytic processes and the prostaglandin pathway through COX 48	
enzyme production. While reactive oxygen species (ROS) are important molecules 49	
regulating numerous physiological and pathological processes in the cell, there is now 50	
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clear evidence that overproduction of ROS is involved in the development of a 1	
number of diseases such as Alzheimer’s disease, rheumatoid and cardiovascular 2	
diseases. Increasing evidence supports the notion that low concentrations of ROS or 3	
‘primary ROS’ are involved in well controlled processes (44) where their effect on 4	
reactive target molecules can be reversible, suggesting that ‘primary’ ROS acts as an 5	
important intracellular signalling molecule (45). In contrast, the very active .OH ROS 6	
is less effectively controlled and forms the main damaging type of ROS that is able to 7	
react with many macromolecules such as lipids, proteins and nucleic acids. This 8	
results in DNA oxidation and cell membrane damage, which contributes to the burden 9	
of damaged molecules related to aging and age-related diseases.  10	
 11	
3.1.1 Mitochondrial ROS 12	
Mitochondria are highly efficient producers of energy but in doing so they produce 13	
ROS. It is estimated that about 90% of intracellular ROS is generated in the 14	
mitochondria through the mitochondrial transport chain. The chain of electron flow is 15	
considered to leak prematurely between complexes 1, 11 and 111 leading to the 16	
formation of damaging oxidants like O2.-. This ROS has been considered to cause 17	
damaging mutations in the mitochondrial genes with increasing age (43). With 18	
increasing age, mitochondrial function becomes sluggish and this compromises 19	
energy production, which in turn further contributes to mitochondrial dysfunction 20	
(46). A vicious cycle develops with age-reduced physical activity producing muscles 21	
that become weaker, are infiltrated with fat cells, and show less efficient mitochondria 22	
energy production (47). Ischaemia and apoptosis can trigger O2.- and mitochondria 23	
themselves can be damaged by ROS production. Mitophagy, the removal of damaged 24	
mitochondria is also reduced as age increases (48). A reduced age-related capacity of 25	
the body’s anti-oxidative defence systems to mop up free radicals also plays an 26	
important role in maintaining the inflammatory background of chronic inflammation 27	
(49).  28	
 29	
3.1.2 The NADPH pathway of ROS  30	
One of the other main producers of ROS is the specialised enzyme group of the 31	
nicotamide adenine dinucleotide phosphate (NADPH) oxidases of the NOX family-32	
(NOX1, NOX2, NOX3 NOX4, NOX5, DUOX1 and DUOX2). The NOX family or 33	
NADPH oxidases’ generate O2.- or H2O2 radicals by transferring electrons from 34	
cytoplasmic NADPH or the ‘NOX’ catalytic subunit to molecular oxygen (50). The 35	
ROS produced by these enzymes has an essential function in neutrophils and 36	
macrophages as a mechanism for effective bacterial killing and host defence (51,52). 37	
When the phagocytes sense an endogenous or exogenous danger signal, the NADPH-38	
oxidase unit translocates to fuse with the plasma membrane to form the phagosome. 39	
This generates large amounts of highly reactive ROS called the phagocytic burst that 40	
is very effective in killing microbes, though phagosomal pH and ion concentration are 41	
also likely to contributors.  42	
 43	
Although NOX family of isoenzymes was initially associated with the ROS produced 44	
in phagocytes, other members of the NOX family are now known to be involved in a 45	
wide range of regulatory functions in many tissues and seem likely to play a role in 46	
aging and age-related diseases. Studies in the human vascular system suggest that 47	
NOX1, NOX2, and NOX5 promote endothelial dysfunction, inflammation, and 48	
apoptosis in the vessel walls, whereas NOX4 by contrast is vasoprotective, by 49	
increasing nitric oxide bioavailability (53). NOX enzymes therefore appear to play a 50	
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role in vascular pathology as well as in the maintenance of normal physiological 1	
vascular function. Activation of NOX2 and NOX4 occurs in humans with atrial 2	
fibrillation and inhibition of NOX by Angiotension Converting Enzyme (ACE) 3	
inhibitor drugs or statins has proved helpful in preventing post-operative atrial 4	
fibrillation (54).  5	
 6	
3.1.3 COX pathways of ROS 7	
The bio lipids are highly reactive substances that contribute to both inflammation and 8	
healing and their pathways produce and use ROS signalling. The reaction that 9	
converts cyclooxygenase-2 (COX-2) to arachidonic acid and into prostaglandin H2 10	
(PGH2) by a two-stage free radical mechanism (55) involves superoxide and can 11	
contribute to cellular oxidative stress as well as signalling. Other enzymes that 12	
generate ROS during arachidonic acid metabolism include the arachidonate 12-13	
lipoxygenase (LOX-12 or ALOX12) and arachidonic -5-lipoxenase (LOX5 or 14	
ALOX5), both of which also activate and induce NADPH-oxidases (56).  15	
 16	
While mitochondrial ROS are traditionally seen as the main source of intracellular 17	
ROS and therefore major mediators of ROS-induced damage, the relative contribution 18	
of mitochondrial and non-mitochondrial sources of ROS to induction of cellular 19	
senescence remain unclear. Both mitochondrial ROS and NADPH-produced-ROS 20	
appear to be able to cross signal between each other and mitochondria have 21	
significant anti-oxidant capacity, which may act as a cellular redox buffer for 22	
NADPH-produced-ROS, suggesting there is tight control and integration of ROS 23	
signalling within the cell. 24	
 25	
The cellular systems that protect against ROS include the anti-oxidative defense 26	
enzymes, (superoxidase dismutase (SOD), glutathione peroxidase (GPx) and catalase 27	
(57), oxidant scavengers (vitamin E, vitamin C, carotenoids, uric acid and 28	
polyphenols) and mechanisms to repair oxidant damage to lipids, proteins or DNA. 29	
Despite these protective mechanisms, uncontrolled ROS can overwhelm the 30	
antioxidant capacity of the cell causing mitochondrial dysfunction (49). Increased 31	
ROS production from the various cellular sources stimulates intracellular danger-32	
sensing multi-protein platforms called inflammasomes (58-60). Through the 33	
inflammasome the ROS activates NF-κb which sets in motion the transcription of a 34	
cascade of pro-inflammatory cytokines - TNF-α, IL-1β, IL-2 and IL-6, chemokines -35	
IL-8 and RANTES, and adhesion molecules such as ICAM-1, VCAM and E-Selectin, 36	
that are central mediators in the inflammatory response.  37	
 38	
3.2. Autophagy slowing and aging 39	
Approximately a third of all newly synthesised proteins are formed in the 40	
endoplasmic reticulum (ER), where they are folded, modified, sorted and transported 41	
to sites where they perform specialised roles. Stressors such as low glucose as in 42	
fasting, alterations in calcium levels, low oxygen states, viruses, cytokines and 43	
nutrient excess or deficiency can trigger the autophagy pathway with the aim of 44	
returning normal homeostasis to the cell.  45	
 46	
Autophagy is a cellular process whereby cellular waste such as modified proteins, 47	
protein aggregates and damaged organelles are removed from the cell. It is a tightly 48	
controlled process that plays a role in growth and development and maintains a 49	
balance between the synthesis, degradation and subsequent recycling of cellular 50	
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products. Autophagy can be considered a protein and organelle quality control 1	
mechanism that maintains normal cellular homeostasis.  2	
 3	
Two major pathways degrade cellular proteins. The ubiquitin-proteasome system 4	
(UPS) degrades 80-90% of denatured and damaged proteins. In the ATP-dependent 5	
ubiquitin-proteasome system, damaged or misfolded proteins are tagged with a small 6	
protein called ubiquitin. Three different sets of enzymes -E1, E2, and E3, identify and 7	
categorise proteins in order to link ubiquitin or ubiquitin complexes to the damaged 8	
proteins. The ubiquitin-protein complexes pass through the proteasome where they 9	
are degraded and discharged as free amino acids into the cytoplasm (Fig 3a).  10	
 11	
The other main pathway is the autophagy system that degrades cystolic components 12	
including larger aggregated proteins and cellular organelles such as mitochondria, 13	
peroxisomes and infectious organisms (61). This process involves membrane 14	
formation, fusion and degradation (Fig 3b). When autophagy is induced a small 15	
separate membrane structure called a phagophore arises in the cytoplasm, which 16	
gradually expands to form the autophagosome. The outer membrane of the 17	
autophagosome fuses with the lysosome and the autophagosome contents are 18	
degraded by lysosomal hydrolases (62). Like the proteasome, the macroautophagy 19	
system is stimulated by intracellular and extracellular stress-related signals including 20	
oxidative stress. Both proteasome and autophagy produce small polypeptides that help 21	
maintain a pool of amino acids and control energy balance in starvation, since 22	
recycling amino acids is more energy efficient than de novo amino acid synthesis.  23	
 24	
In aging and age-related disease there are gradual reductions of cellular repair 25	
mechanisms that lead to the accumulation of damaged molecules, proteins, DNA, and 26	
lipids leading to loss of efficient cellular function. The cell’s capacity for autophagic 27	
degradation also declines with age, and this in itself may contribute to the aging 28	
process (63). While both major systems for intracellular protein degradation are 29	
slowed up with increasing age, a physical reduction of autophagy-related proteins also 30	
contributes to the accumulation of misfolded proteins and damaged macromolecules 31	
in the cell. Diseases associated with increased oxidative stress such as cardiovascular 32	
and Crohn’s disease and obesity also slow up cellular clearing and reduce autophagy, 33	
further contributing to disease (64-66). 34	
 35	
The lysosome-autophagy system carries out a wide range of non-specific intracellular 36	
degradation and cleaning processes, which include managing pathogens, damaged 37	
intra-cellular macromolecules and surface receptors (67-69). Lysosomal dysfunction 38	
is associated with many age-related pathologies that reduce lifespan, such as 39	
Parkinson’s and Alzheimer’s diseases (70,71). Senescent cells accumulate abnormal 40	
protein aggregates in the cytoplasm, which contribute to neurodegenerative disease 41	
(72).  42	
 43	
The dysregulation in autophagy has important effects in the innate immune response, 44	
in aging and age-related diseases by influencing inflammasome activity, cytokine 45	
secretion, antigen presentation and lymphocyte function (73,74).  Under normal 46	
circumstances the NLRP3 inflammasome fine-tunes the progression of the innate 47	
immune response that it has initiated, by upregulating autophagy activity so that the 48	
removal of immune mediators is expedited (74). In aging and age-related diseases the 49	
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autophagy response becomes blunted, the immune mediators remain active and 1	
prolong the inflammatory response (75).  2	
 3	
The ubiquitin-proteasome system and autophagy act synergistically and cooperatively 4	
to maintain cellular homeostasis (76). Effective autophagic uptake of dysfunctional 5	
mitochondria and efficient lysosomal degradation of damaged aggregated proteins 6	
and macromolecules are crucial elements in maintaining tissue homeostasis and good 7	
health (77). The decline in the autophagy capacity, that impairs cellular housekeeping 8	
in ageing, seems an attractive molecular pathway to target to improve the quality of 9	
aging.  10	
 11	
Two groups of drugs, the mammalian target of rapamycin (mTOR) inhibitors and 12	
AMP-activated protein kinase (AMPK) activators are promising pharmacological 13	
agents which stimulate autophagic degradation (78-80). Other drugs such as the 14	
diabetic drug metformin and the oncology agent 5-aminimidazole-4 carboxamide 15	
ribonucleoside are pharmacological activators of AMPK, which are soon planned for 16	
clinical studies in relation to aging (81-83). A number of substances such as 17	
curcumin, berberine and quercetin, regularly contained in normal diets, appear able to 18	
mimic the action of AMPK and up-regulate autophagy. The action of AMPK has 19	
important anti-inflammatory and immunosuppressive effects (83). By up-regulating 20	
autophagic activity AMPK promotes effective clearing of DAMPs and by preventing 21	
the activation of the inflammasome, it reduces the triggering of the inflammatory 22	
cascade. Further evidence of the anti-inflammatory role comes from research with the 23	
AMPK agonist A-769662 that mimics AMPK activity (84). This AMPK mimetic has 24	
been shown to suppress inflammatory arthritis in mice and reduce IL-6 expression in 25	
serum and arthritic joints, suggesting that targeted AMPK activation could be an 26	
effective therapeutic strategy for IL-6-dependent inflammatory arthritis (85).  27	
 28	
Non-pharmacological life-style changes also up-regulate autophagy. One of the best 29	
researched is the effect of exercise which improves mitochondrial mitogenesis and 30	
stimulates mitogeny, so improving the quality of muscle function and exercise 31	
performance, with improvement in the quality of aging (86-88). Furthermore in 32	
animal model studies, both modulated caloric restriction and exercise increase 33	
autophagy, down regulate endotoxin-induced IL-1β production, improve the aging-34	
related pro-inflammatory profile and reduce disease symptoms (89,90).  35	
 36	
Further understanding of molecular pathways of the signaling networks underpinning 37	
autophagy should help identify other novel drug targets. Important research areas 38	
include those that could improve the sensitivity of degradation inhibitors useful to 39	
improve anticancer treatment, or new drugs to up-regulate autophagy to maintain 40	
good cellular housekeeping, with the potential for improving the quality of ageing and 41	
the management of age-related degenerative diseases.  42	
 43	
3.3. Senescent cells  44	
Senescent cells increase with age and are considered important contributors to the 45	
pro-inflammatory phenotype (91). The two major hallmarks of cellular senescence are 46	
an irreversible arrest of cell proliferation and production of the pro-inflammatory 47	
secretome, called the senescence-associated secretory phenotype (SASP). When 48	
replicative senescence was first identified in serial cell passage studies (92), telomere 49	
attrition was considered to cause the cellular growth arrest that acted as a mechanism 50	
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to stop damaged or transformed cells from proliferation and transiting to tumour 1	
initiation. Today senescence is considered to have much broader role as both a 2	
contributor to damage protection and in the control of cellular growth, or as both a 3	
‘friend and foe’ depending on the cellular context. Senescence together with apoptosis 4	
is recognized to play an important physiological role in normal embryonic 5	
development, in ongoing tissue homeostasis throughout life (93,94), but is 6	
increasingly considered to have a role in causing or exacerbating aging and age-7	
related diseases (93,95-97).  8	
 9	
Senescence is a stress response triggered not only by telomere attrition as originally 10	
described (92,98), but also by stress insults such as genomic instability, DNA 11	
damage, protein misfolding and/or aggregation and ROS. There is also an association 12	
between senescent cells and the dysregulated mitochondrial network and associated 13	
metabolic dysfunction that is seen with increasing age (99). Through the SASP the 14	
senescent cell has an important influence on the extrinsic microenvironment, which 15	
suggests a link between senescence and alterations in intracellular and intercellular 16	
communications (95). 17	
 18	
Cells that express senescence markers accumulate with age in some tissues in studies 19	
in mice and man (100-102). Senescent cells are found in association with age-related 20	
diseases such as atherosclerosis, rheumatoid arthritis (RA), neurodegenerative 21	
diseases and cancer (103-106). In rheumatoid arthritis (RA) patients T-cells are 22	
described as showing a pre-aged phenotype with apparent loss of CD28 expression 23	
that reduces T-cell activation and this in association with reduced RA-related NK 24	
surveillance, could allow senescent cells and the associated SASP to persist. In cancer 25	
SASP factors promote angiogenesis, cell proliferation and cancer invasiveness. Cells 26	
attracted by SASP influence the local microenvironment with the potential to promote 27	
tumour invasion and cancer progression (107). Senescent cells have been seen in 28	
atherosclerotic plaques (103). Recent data from several laboratories has suggested that 29	
both aging and age-related neurodegenerative diseases show an increase in SASP-30	
expressing-senescent cells of non-neuronal origin in the brain, which correlated with 31	
changes in neurodegeneration (105).  32	
 33	
The SASP consists of a complex combination of growth factors, proteases, 34	
chemokines, matrix metalloproteinases and is particularly enriched in pro-35	
inflammatory cytokines, especially IL-6 (108-110). The SASP-secreting cells respond 36	
by switching on a self-perpetuating intracellular pro-inflammatory signaling loop, 37	
centered around the NF-κB, TGF-β, IL-1α, IL-6 pathway (111-113), with suggested 38	
mechanisms related to higher basal phosphorylation and altered threshold signaling 39	
(114) or alternative splicing (115). Senescent cells influence other cells by paracrine 40	
and bye-stander effects (116). There appears to be multi-level control of senescence 41	
and the SASP secretome, which includes the tumour suppressor pathways involved in 42	
the cell cycle arrest and the NF-kB and persistent damage response (DAMP) pathway, 43	
involved in triggering transcription of the SASP-related factors (117). Several 44	
pathways of investigation suggest that senescent primary human CD8+ T cells use 45	
anaerobic glycolysis to generate energy for effector functions and that p38 Mitogen-46	
activated protein kinase (p38 MAPK) blockade may reverse senescence via the 47	
mammalian target of rapamycin m-TOR (m-TOR)-independent pathway (118). Low 48	
doses of glucocorticoid suppress elements of the SASP in patients with rheumatoid 49	
arthritis and improve clinical symptoms (119). Senescent cells effectively recruit the 50	
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immune system to organise their removal, but with increasing age, removal becomes 1	
sluggish or otherwise impaired (120,121).  2	
 3	
It can be argued that the increase in senescent cells with aging reflects either an 4	
increase in their rate of generation or a decrease in their rate of clearance because the 5	
immune response is attenuated or weakened with aging and less capable of clearing 6	
senescent cells (122-124). Senescent cells express ligands for cytotoxic immune cells 7	
such as natural killer (NK) cells, and have been shown to be able to be specifically 8	
eliminated by the immune system (125,126). Through a proteomics analysis of 9	
senescent cell chromatin, the NF-κB pathway appeared to act as a master regulator of 10	
the SASP, with NF-κB suppression causing escape from immune recognition by (NK) 11	
cells (127). Other studies show that processes which eliminate senescent cells with 12	
p16(Ink4a)-positive markers, delay age-related pathologies in the mouse model of 13	
aging though side-effects can be problematical (128,129). Therapies that specifically 14	
recognize and trigger the elimination of senescent cells would seem important ways to 15	
enhance the immune system in older people. New methods are in the process of being 16	
developed to enhance the immune clearance and autophagy of the increased senescent 17	
cell burden in aging and age-related disease (130).  18	
 19	
3.4 Inflammasome NLRP3  20	
The inflammasomes, intra-cellular multiprotein sensors that recognise danger signals, 21	
are likely key players in initiating and maintaining the pro-inflammatory phenotype 22	
found associated with aging. The Nod-like receptor 3 (NLRP3) is a major 23	
inflammasome sensor for intracellular stress molecules called danger-associated 24	
molecular patterns (DAMPs), which together with damaged aggregated proteins that 25	
are released from destabilised lysosomes and damaged mitochondria contribute to the 26	
cellular stress (ROS) and trigger NLRP3 activation (131). Once activated, the NLRP3 27	
inflammasome initiates the inflammatory response cascade by stimulating caspase-1 28	
(CASP-1) that acts to induce the active precursors of pro-inflammatory cytokines IL-29	
1β, IL-1α and IL-18, and on-going interaction with NF-κB (132,133) (Fig 4). 30	
Although the baseline activity of NLRP3 is low, the initiation process of the 31	
inflammatory cascade requires a complex oligomerisation-priming phase that includes 32	
association with NF-κB and so contributes several layers of regulatory control.  33	
 34	
NLRP3 has also been shown able to activate NF-κB and induce cytokines in response 35	
to sterile signals, such as monosodium urate crystals and aluminum adjuvant, 36	
suggesting that NLRP3 could initiate NF-κB activation to both pathogen-induced and 37	
sterile inflammation (134). Conversely NF-κB, which primes the NLPR3 38	
inflammasome for activation also prevents excessive inflammation and restrains 39	
NLRP3 activation by enhancing the NF-κB-p62 mitophagy pathway. By self-limiting 40	
the host response the NF-κB-p62 mitophagy pathway maintains homeostasis which 41	
under normal conditions leads to tissue repair (75). It is however unclear if this layer 42	
of control of NF-κB function remains as tightly controlled in aging and age-related 43	
disease.  44	
 45	
The NLRP3 inflammasome is a key component of the innate inflammatory response 46	
to pathogenic infection and tissue damage (Fig 6). It responds to a wide range of 47	
cellular stress and is considered to contribute to the aging process and to age-related 48	
diseases (135). Zhou and colleagues identified that mitochondrial ROS was involved 49	
in the activation of NLRP3 (58). This study emphasized the important role of 50	
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mitochondria in maintaining a correct balance between cellular energy production and 1	
ROS production and that effective clearance of damaged mitochondria through 2	
autophagy was an important regulatory activity. Damaged mitochondria increase with 3	
aging and in age-related diseases (136). Mitochondrial dysfunction drives 4	
mitochondrial mutagenesis, affecting respiratory chain genes and compromising the 5	
efficiency of oxidative phosphorylation (OXPHOS), which may lead to further 6	
mtDNA mutations and more cell damage. The subsequent mitochondrial impairment 7	
leads to more ROS that further reduces ATP generation and increases the chance of 8	
cell death. Mitochondria have been identified as a key source of DAMPs, the so-9	
called mito-DAMPs, which have been considered to play a role in DAMPS-10	
modulated inflammation in diseases such as rheumatoid arthritis (RA), cancer and 11	
heart disease (137-140) as well as in the aging process (141). Degraded mt-DNA has 12	
been also been reported in neuroinflammation (142). Dysfunctional mitochondria 13	
seem able to initiate an auto-feedback loop to increase autophagy so that damaged 14	
mitochondria or misfolded proteins are degraded that reduces inflammasome 15	
activation and risk of further tissue injury, though this system is less efficient in aging 16	
(143).  17	
 18	
Lyosomal destabilization is also associated with NLRP3 activation and can be 19	
induced by a number of molecules including cholesterol crystals in macrophages 20	
linking atherosclerosis progression with inflammation (144). There is deposition of 21	
other harmful intra-and extracellular material in several age-related diseases. The 22	
aggregates compromise cellular homeostasis and can provoke the activation of the 23	
NLRP3 inflammasome. Research has shown that amyloid fibrils and Alzheimer’s 24	
amyloid–β can trigger NLRP3 inflammasomes and in that way stimulate 25	
inflammation and enhance pathogenesis and association between type 2 diabetes and 26	
Alzheimer’s disease respectively (145). Palmitate, a saturated fatty acid has been 27	
shown to activate NLPR3, whereas oleic acid did not initiate the same inflammatory 28	
response (146). The inflammasome has been implicated in the development of the 29	
metabolic syndrome through impairment of adipose tissue sensitivity. Evidence 30	
showed that obesity triggered NLRP3 activation and that the secreted IL-1β impaired 31	
insulin signaling which promoted insulin resistance in mice (147). Other research has 32	
shown that obesity was associated with the activation of the NLRP3 in adipose tissues 33	
(148,149).  34	
 35	
A number of intracellular processes seem likely to work together to stimulate and 36	
augment the inflammasome pathway and contribute to pro-inflammatory cytokine up-37	
regulation associated with increased age and age-related diseases. Both the redox-38	
sensitive inflammatory pathway and the senescent cell-related-SASP activate the 39	
inflammasome through the NF-kB and IL-a cascade, causing persistence of the 40	
inflammatory response, that delays resolution and healing (140,127). Similarly 41	
reduced autophagy processes allow the accumulation of damaged intracellular 42	
proteins and senescent cells that further perpetuate and amplify the pro-inflammatory 43	
milieu that is found with increased age and is associated with age-related diseases.  44	
 45	
4. Pro-inflammatory and anti-inflammatory cytokine dysregulation  46	
 47	
4.1. Pro-inflammatory cytokines in aging and age-related disease  48	
Various biomarkers and biochemical indices are used in medicine and age-related 49	
diseases as a way of improving diagnosis, beyond the well-recognised clinical signs. 50	
In r vi
ew
	 14	
Modest increases in concentration of C-reactive protein, a circulating marker of 1	
inflammation, have been widely reported to be associated with a large number of age-2	
related conditions and lifestyles felt to be associated with poor health; these 3	
conditions represent or reflect minor metabolic stresses. Alongside C-reactive 4	
proteins, cytokines have come under investigation as the molecular processes and 5	
pathways underpinning inflammation have become better identified. A common 6	
finding in aging and age-related diseases is ‘inflamm-aging’, a dysregulation of the 7	
cytokine network and its homeostasis. Downstream from NF-κB signaling, the pro-8	
inflammatory cytokines play a central role in the remodeling of the immune system 9	
with age.  10	
 11	
The major pro-inflammatory cytokines such as IL-6, TNF-α and IL-1α contribute 12	
significantly to the phenomenon of inflamm-aging in healthy elderly individuals (8), 13	
while also playing a major role in many age-related diseases (11,27,150-153). The 14	
key to healthy aging must lie in the ability to maintain a balanced response to these 15	
immune messengers and a prompt and integrated return to inflammation resolution 16	
and immune homeostasis (17). A summary of the changes that have been described in 17	
pro-inflammatory and anti-inflammatory cytokines in aging and some age-related 18	
diseases are outlined in this section.  19	
 20	
4.1.1. Interleukin-1 (IL-1) family  21	
IL-1α and IL-1β, known as Interleukin-1 (IL-1), and IL-18 are important cytokine 22	
initiators of the stress-induced inflammatory cascade (154). IL­1β and IL­18 are 23	
cleaved to active forms by caspase 1 (Casp-1), whereas IL­1α is activated by calpain 24	
protease. All bind to and activate the IL-1 receptor (IL-1R) that is down regulated by 25	
the receptor anatagonist IL-1Rα, which blocks IL-1 mediated signal transduction.  26	
 27	
Studies in elderly people, including centenarians have reported an age-related rise in 28	
the IL-1 receptor antagonist, (IL-1Rα), whereas IL-1β showed no detectable age-29	
related trend. The age-related rise is associated with increased co-morbidity, age-30	
related disease and mortality (155-158).  31	
 32	
Certain IL-1 haplotype-carriers produce increased IL-1β, and IL-1 gene variations 33	
associate with earlier onset or more severe progression of cardiovascular and 34	
Alzheimer’s disease, but not with osteoporosis (159-163). In centenarians, no single 35	
IL-1 gene polymorphism showed a survival advantage, but in Swedish elderly males 36	
an IL-1 gene polymorphism shortened life expectancy (164,165,155). IL-1 gene 37	
variants appear to increase the risk of age-related diseases and recombinant drugs, 38	
such as IL-1Rα-blockers may have a role in the clinical control of inflammation 39	
(166). 40	
 41	
4.1.2. Interleukin-18 (IL-18)  42	
Interleukin (IL)-18, a linked IL-1 pro-inflammatory cytokine, signals in a complex 43	
with IL-18 receptors α(Rα) and β(Rβ) chains and induces IFN-γ that is essential for 44	
defence against infections (167). IL-18’s multiple pro-inflammatory effects are 45	
modulated through IL-18 binding protein (168).  46	
 47	
Higher levels of IL-18 have been found in centenarians, associated with heart failure, 48	
ischemic heart disease and type-1 diabetes in patients, and in the Alzheimer’s disease 49	
brain (169-174). IL-18 levels associate with physical functioning and with a frailty 50	
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index in the English Longitudinal Study of Aging, where carriers of IL-18 gene 1	
polymorphism that reduced IL-18 levels, showed improved walking speed (175-177). 2	
Evidence consistently shows that IL-1 and IL-18 are mediators of inflammation and 3	
associated with the aging process (170). Drugs blocking binding between IL-18 and 4	
the receptors are currently in development and may be provide benefit in the 5	
treatment in diabetes, macular degeneration and autoimmune disease (178). 6	
 7	
4.1.3. Interleukin-6 (IL-6)  8	
IL-6 has been long recognised as important in aging and age-related disease and has 9	
been called the ‘gerontologist’s cytokine’ (179,180). IL-6 plays a key role in the acute 10	
phase response, in the transition from innate to acquired immunity, in metabolic 11	
control and in the pathogenesis many chronic diseases (11,150-153,181). It has both 12	
pro- and anti-inflammatory activities and modulates the acute inflammatory response 13	
by producing IL-1 Rα and soluble TNF-receptor p55, (sTNF-R55), that suppress 14	
TNF-α and IL-1.  15	
 16	
IL-6 is normally present in low levels in the blood, but is increased in aging and in 17	
subjects with markers of frailty and chronic disease, where it tracks with mortality 18	
(182-185). IL-6 is a risk factor associated with cardiovascular disease and is 19	
associated with sarcopenia and muscle loss (186,187). 20	
 21	
The G allele of IL-6-174C/G polymorphism shows higher IL-6 levels and associates 22	
with cognitive decline and mortality in age-related vascular disease, whereas CC 23	
allele carriers show decreased Alzheimer’s risk (188-193). In a meta-analysis of 24	
longevity in a large cohort of European nonagenarians and centenarians there was 25	
longevity benefit for carriers of the lower cytokine producing IL-6 allele, with similar 26	
supporting findings for this IL-6 allele in a case control study (194,195). IL-6 or IL-6 27	
receptor blockers are already used successfully in the treatment of rheumatoid 28	
arthritis, and are proof of concept that damping down IL-6, a product of the NF-κB 29	
pro-inflammatory cascade, can improve clinical symptoms. Studies are in either in 30	
progress or planned, to assess the outcome of blocking IL-6 related inflammation in 31	
other age-related diseases with the potential for contributing to more successful aging 32	
(196,197).  33	
 34	
4.1.4 Tumour Necrosis alpha (TNF-α) 35	
Another major player in the immune response is the pro-inflammatory cytokine TNF-36	
α, which increases with age and is associated with age-related disease (198). It is a 37	
pro-inflammatory mediator that can be beneficial when it acts locally in the tissues, 38	
but can be highly harmful when released systemically.  39	
TNF-α has been reported increased in intracellular ageing studies in elderly people, in 40	
centenarians and octogenarians, related to atherosclerosis and associated with 41	
mortality (199-204). In post-myocardial infarction patients, a rise in TNF-α increased 42	
risk of recurrent cardiac events and in renal patients TNF-α receptors predicted 43	
cardiovascular disease (205-207). In genetic studies, the A allele of TNF-α 308-G/A 44	
gene associated with risk for myocardial infarction, whereas TNF-α polymorphisms 45	
and TNF-α itself, have been variably associated with increased Alzheimer’s disease 46	
risk (208-212). TNF-α mediates metabolic changes and increased TNF-α was found 47	
in type II diabetes mellitus and was associated with lower muscle mass and strength 48	
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in older groups (213). 1	
In studies in nonagenarian/centenarian groups from three European countries, there 2	
was no attrition of the TNF-α-308A/G polymorphism in centenarians (214,215,164). 3	
With increasing evidence of an association between increases in TNF-α and age-4	
related diseases, research re-purposing anti-inflammatory drugs are under 5	
development. Research has demonstrated that TNF-α inhibitors may have possible 6	
prophylactic or ameliorating roles in cardiovascular and Alzheimer’s disease in 7	
animal models (216,217).  8	
4.1.5 Other pro-inflammatory cytokines  9	
Other pro-inflammatory cytokines are increasingly being recognized as dysregulated 10	
in association with aging and age-related disease.  11	
IL-2 12	
IL-2 plays a pivotal role in the immune response. It is a growth factor that promotes 13	
natural killer cell (NK) activity and the differentiation of naïve T cells into Th1 and 14	
Th2 cells (218). Conversely, IL-2, acting via STAT5 pathway negatively regulates IL-15	
17 production (219). Most studies show that lymphocytes in elderly people produce 16	
significantly less IL-2, compared to young people (220-222). Intracellular cytokine 17	
studies have shown variable results for IL-2, whereas mitogen-induced stimulation of 18	
mononuclear from elderly subjects showed significant decreases in IL-2 and IFNγ 19	
production (223,224). 20	
The IL-7/IL-7R  21	
The IL-7/IL-7R network is essential at various stages in T-cell development and 22	
survival (216). It has an important role in the maintenance of a vigorous health span 23	
and higher IL7R gene expression is associated with long life (225-228). Serum IL-7 is 24	
increased in some age-related diseases including osteoarthritis and genetic variation in 25	
the IL7RA/IL7 pathway increased susceptibility to multiple sclerosis (229,230). 26	
Research has suggested that silencing of the IL-7R gene may be an important 27	
mechanism underpinning an aging-related loss of binding to NK-κB (231), linking 28	
IL-7R gene to the NF-κB pathway and inflammation control.  29	
IL-12, a pro-inflammatory member of the IL-6 family has an active role in the 30	
development of cardiovascular diseases such as atherosclerosis, myocardial infarction 31	
(MI) and stroke (232). Patients with cardiovascular disease show increased levels of 32	
IL-12, 23 and 27 with higher IL-12 predicting poorer long-term outcome after acute 33	
MI (233). Other research shows variable results for IL-12 and its receptor antagonist, 34	
with increased IL-12 (total) and IL-12p40 in apparently healthy nonagenarians, lower 35	
IL-12p70 and IL-23 production in association with frailty and IL-12/23.p40 36	
ameliorating Alzheimer’s disease in animal models (234-236). 37	
IL-17 38	
Interleukin 17 (IL-17) is a key pro-inflammatory cytokine that belongs to a family of 39	
6 cytokine members (A-F). IL-17A (referred to as IL-17) plays a central role in host 40	
defense against invading pathogens and is produced by a subset of CD4+cells 41	
(237,238). Elderly people (age ≥ 65) have shown a decreased frequency of IL-17-42	
producing cells in memory subset of CD4 + T cells compared to healthy younger 43	
people (239). IL-17 enhances production of IL-6, TNF-α, the acute phase reactants, 44	
C-reactive protein and serum amyloid A and activates the induction of IL-6, IL-8 and 45	
G-CSF in non-immune cells such as fibroblasts and epithelial cells, in part through 46	
activation of the NF-κB transcription factor (240). IL-17 promotes inflammation and 47	
is over-expressed in many autoimmune diseases such as rheumatoid arthritis, systemic 48	
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lupus erythematosus, inflammatory bowel disease and psoriasis and its effects are 1	
stabilized by IL-23 (241-244). An IL-17 expressing CD8+T subset of cells has also 2	
been reported to be involved in psoriatic arthritis and some other autoimmune 3	
diseases (245,246).  4	
Interleukin-8 (IL-8) 5	
IL-8 (or CXCL8) is a chemokine secreted by monocyte/macrophages whose key role 6	
in the inflammation process is the recruitment and activation of neutrophils. IL-8 has 7	
been implicated in a number of inflammatory conditions such as cystic fibrosis, 8	
asthma, chronic pulmonary disease, inflammatory bowel disease and some 9	
autoimmune diseases, including rheumatoid arthritis and psoriasis.  10	
Increased levels of IL-8 have been detected after LPS-stimulation of leucocytes from 11	
elderly individuals (247) . In one small study of centenarians, IL-8 was proposed as a 12	
possible longevity factor (248). A single study of IL-8 polymorphisms found no 13	
significant difference in IL-8 -251A/T polymorphisms in nonagenarians compared to 14	
young controls (214). IL-8 signalling occurs via the MAPK and PI3K pathways, by 15	
binding to the IL-8 receptors-CXCR1/2. Several agents that block IL-8-CXCR1/2 16	
signalling have been developed in an attempt to target inflammatory pathways in 17	
cancer, asthma, chronic obstructive pulmonary disease, psoriasis and rheumatoid 18	
arthritis (249). 19	
 20	
4.2. Anti-Inflammatory cytokines in aging and age-related Disease  21	
 22	
The anti-inflammatory cytokines play a key role in balancing the immune response, 23	
and in preventing the tipping of the steady state of immune homeostasis across into 24	
inflamm-aging and a disease-inducing state. Anti-inflammatory cytokines are an 25	
important arm of inflammation resolution. They block or modulate the synthesis of 26	
IL-1α, tumor necrosis factor (TNF) and other major pro-inflammatory cytokines and 27	
damp down the inflammatory response, so that inflammation resolution can begin. 28	
Specific cytokine receptors for IL-1, TNF-α, and IL-18, together with soluble receptor 29	
antagonists, chemokines, microRNA, siRNAs, also function as inhibitors for pro-30	
inflammatory cytokines. The anti-inflammatory cytokines and families of soluble 31	
receptor antagonists work within a complex network of control of immune regulation. 32	
They are critical for balancing the inflammatory outcome and together with pro-33	
resolving lipoxins, are critical to resolving inflammation in an integrated and 34	
organized manner.  35	
 36	
As age increases and in age-related diseases, a chronic inflammatory state 37	
predominates, which is not properly contained or resolved and the anti-inflammatory 38	
side of the immune system seems to be similarly dysregulated, and unable to damp 39	
down the inflammatory episode in a timely effective manner. The following cytokines 40	
are the major players in the anti-inflammatory pathway of the control of inflammation 41	
and changes in their production and expression have been quite widely reported in 42	
aging and age-related disease. Where increases in anti-inflammatory cytokines have 43	
been reported, one interpretation would be that increases might reflect the immune 44	
system’s attempt to suppress the persistent pro- inflammatory response and support a 45	
return to immune homeostasis.  46	
 47	
4.2.1. Interleukin 10 (IL-10) family    48	
IL-10 is one of the key anti-inflammatory cytokines, which suppresses the actions of 49	
IL-6, TNF-α and IL-8 (250,251). Higher IL-10 serum levels and production by both 50	
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lymphocytes and monocytes have been reported in elderly people (247, 252,157). 1	
Conversely an age-and gender-related decline in cellular stimulation studies has been 2	
reported (253). 3	
 4	
In age-related disease, IL-10 has been reported to be associated with vascular 5	
protection in atherosclerosis and improved endothelial dysfunction (254-256). 6	
However, at variance, the authors from the ERA (257) and PROSPER (258) studies, 7	
concluded that IL-10 increased cardiovascular risk amongst elderly groups, and 8	
suggested that IL-10 blockers merited investigation. In male Sicilian centenarians, 9	
male carriers of the high producing GG 1082 allele of the IL-10 promoter 10	
polymorphism showed a survival advantage, suggesting that IL-10 anti-inflammatory 11	
activities might be a marker for male longevity (215). This result was not replicated in 12	
Sardinian, Irish or Finnish nonagenarian/centenarians (259,214,164). It has been 13	
argued that an enhanced anti-inflammatory phenotype could be beneficial and 14	
contribute to longevity by controlling the pro-inflammatory milieu that predominates 15	
in later life and contributes to increased morbidity and mortality (260,9,11).  16	
 17	
4.2.2. TGF-β  18	
TGF-β, another important anti-inflammatory cytokine limits both the acute phase 19	
response, and is involved in tissue repair post-damage or infection (261). Several 20	
authors have reported that TGF- β was increased in octogenarians and centenarians 21	
(262,150). It is also involved in aging-related disease such as obesity, in vascular wall 22	
integrity, in muscle loss and sarcopenia, in osteoarthritis and with frailty in the 23	
Newcastle longitudinal study (263-267). In stroke TGF-β signaling was increased in 24	
microglia and macrophages suggesting that increased TGF-β likely regulated glial 25	
scar formation (268). Reports have linked TGF-β or its polymorphisms with 26	
atherosclerosis and Alzheimer’s disease (269-271). Other research found TGF-β 27	
genotypes associated with longevity in Italian centenarians, a finding not replicated in 28	
BELFAST nonagenarians (272,214). Context-specific environmental factors, 29	
epigenetic regulation and non-coding RNAs are suggested to play a role in TGF-β’s 30	
paradoxical pro-and anti-inflammatory functions (7,273, 274), but important uses 31	
have been found for TGF-β in fibrosis management and oncology (275). 32	
 33	
4.2.3. IL-37  34	
IL-37, formerly an IL-1 cytokine, limits innate inflammation via suppression of pro-35	
inflammatory cytokine production (276). Carriage of an IL-37 haplotype that 36	
decreases IL-37 levels contributes to increased inflammation. Research demonstrates 37	
that IL-37 reduces TNF-α and IL-1β cytokine production from human macrophages, 38	
is increased in chronic heart failure patients and attenuated the production of 39	
inflammatory cytokines in serum or synovial joints in rheumatoid arthritis, suggesting 40	
IL-37 may have a role in clinical disease (277-279).  41	
 42	
Age-related Diseases 43	
5.1. Cancer  44	
Cancer increases with aging, with one in two people likely to develop malignant 45	
tumours in their lifetime. Probable reasons for this age-related increase include 46	
exposure to environmental toxins, declining immune surveillance, and increasingly 47	
ineffective DNA repair mechanisms. Inflammation is involved at different stages of 48	
tumor development, at initiation, promotion, malignant conversion, invasion, and 49	
metastasis, has a paracrine by-stander role and is an essential part of the tumour-50	
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micro-environment. Inflammation also affects immune surveillance and responses to 1	
therapy (280). Thus, malignancy is a major threat to successful aging.  2	
 3	
Whilst inflammatory pathways are vital to promote immune homeostasis, over-4	
activation or dysregulation can be pathological and lead to malignant progression. 5	
Prolonged inflammation, either as a result of chronic infections, or reduced 6	
homeostasis in the inflammatory response, plays a role through the production of pro-7	
inflammatory cytokines that may be directly or indirectly implicated in the 8	
oncogenesis (281,282). More recent investigations have focused on the role of the 9	
inflammasone pathway, whose biochemical function is to activate caspase-1, which 10	
leads to the activation of the IL-1β and IL-18 pathways and induction of pyroptosis, a 11	
form of cell death. Although inflammasomes have an important role in inhibiting 12	
cancer, through the triggering of the programmed-death pathway, they also both 13	
initiate and maintain carcinogenesis, dependent on tumour type and the tumour 14	
environment (283,284). 15	
Bacterial andviral infections are associated with malignancies. For example, 16	
Helicobacter pylori (H pylori) infection of the gut is associated with both gastric 17	
cancer and mucosa-associated-lymphoid-tissue (MALT) lymphoma (285). Epstein 18	
Barr virus (EBV) is a causative agent in Hodgkin’s Disease (HD) where chronic 19	
inflammation is considered a major contributory factor (286), human papilloma virus 20	
(HPV) is implicated in most cases of cervical cancer (287), whilst human T-21	
lymphotrophic virus 1 (HTLV-1) is a causative agent in adult T-cell leukaemia 22	
lymphoma (ATLL) (288). A common factor is the association of infection with 23	
oncogenesis, with chronic inflammation a contributory factor.  24	
 25	
In H pylori chronic infection, elevated levels of IL-1β are detected and recognised as 26	
important in the development of gastric carcinoma. Normally gastric acid in the 27	
stomach does not permit bacterial survival, but in circumstances of low stomach 28	
acidity, H pylori grows vigorously in the mucosa and induces caspase-mediated 29	
cleavage of pro-IL-1β and pro-IL-18 in association with the NLRP3 inflammasome. 30	
The overexpression of IL-1β induces NF-κB activation and the transcription and 31	
expression of IL-6, TNF-α, and IL-10. The proinflammatory cytokine milieu 32	
increases the risk for developing both gastric carcinoma and MALT lymphoma (289). 33	
Persistently high levels of IL-1β and IL-18 suppress acid secretion, allow hypoacidity 34	
in the stomach, loss of parietal cells, gastric atrophy, metaplasia and eventually gastric 35	
cancer. In addition, IL-1β inhibits gastric acid secretion and carriers of IL-1β 36	
polymorphisms producing higher IL-1β carry increased gastric cancer risk (290,291)). 37	
H pylori infection of gastric mucosa can cause a monoclonal B cell proliferation, with 38	
a histological diagnosis of MALT lymphoma. This tumour-like proliferation of gastric 39	
mucosal cells and clonal B cells can regress after eradication of the H pylori infection 40	
with combined antibiotic therapy and proton pump inhibitor treatment (292).  41	
 42	
Viral infections strongly stimulate inflammatory responses and may lead to malignant 43	
transformation of the host cell (293). Although the activation of the inflammasome 44	
benefits the clearance of viruses and the regression of cancer, there are several 45	
examples of viruses such as EBV and HTLV-1 developing strategies to evade 46	
detection, triggering the inflammasome, and high-jacking the inflammatory cascade to 47	
induce and amplify the cancer spread. For example, when EBV infects B-48	
lymphocytes and nasopharyngeal cells through its receptor CD21 (294), this leads to a 49	
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proliferation of infected B cells, followed by an increase in CD8+ T cells that controls 1	
the infected cells by lysis. However, where the normal infection-limiting response is 2	
‘exhausted’ or dysregulated, B-cell proliferation continues unabated leading to 3	
chromosomal damage, which drives cell proliferation outside normal control 4	
mechanisms and may result in an aggressive non-Hodgkin’s or Burkitt’s Lymphoma 5	
(295). NLRP3 activation has been demonstrated in EBV-associated cancerous tissues 6	
(296). Furthermore EBV has been shown to be able to overcome the immune 7	
response by means of EBV miRNA binding to the 3’untranslated region of NLRP3 8	
(297), so preventing effective immune activation and control mechanisms. 9	
 10	
Retro-viruses stimulate inflammatory responses and are associated with malignant 11	
transformation of host cells. They reverse transcribe their RNA into the host cell’s 12	
DNA, leading to dysregulation of cellular proliferation and programmed cell death 13	
responses, and elicit a pro-inflammatory response. HTLV-1 causes adult T-cell 14	
leukemia by targeting CD4+ T cells that express CD25 (IL-2Rα) and FoxP3, similar 15	
to Tregs (298,299). The persistent activation of the NF-κB pathway in HTLV-1–16	
infected T cells and the associated NF-κB oncoprotein Tax contribute to the 17	
oncogenic transformation (300). The resulting hijacking of the NF-κB pathway, 18	
allows uncontrolled upregulation of cellular genes that govern growth-signal 19	
transduction, amplification the pro-inflammatory cytokines (IL-2, IL-6, IL-15, TNF, 20	
together with increasing expression of proto-oncogenes (c-Myc), and antiapoptotic 21	
proteins (bcl-xl) Hiscott Rayet (301,302). Inter-individual susceptibility to HTLV-1 22	
infection has been associated with allele carrier status of the NLRP3 gene (303). 23	
 24	
In summary, the interaction of infective agents, host cells, adaptive immune cells, 25	
cytokine production and the inflammasome response is complex and incompletely 26	
understood. Many cancers arise from sites of infection, chronic irritation and 27	
inflammation, which although sometimes reversible in the pre-malignant phase by 28	
eradicating the causative virus or bacterium, often treatments are too delayed to 29	
prevent the cancer development. There needs to be improved understanding about the 30	
roles of inflammation, the inflammatory cells and the paracrine effects that allow 31	
tumour cell proliferation, survival and migration. Does the pro-inflammatory 32	
environment found in aging enhance and facilitate cancer cell proliferation or does it 33	
alternatively represent an up-regulated immune surveillance mechanism to deal with 34	
increased damaged and dangerous cancer cells? Improved understanding of the 35	
pathways involved should begin to provide insights that could contribute to new anti-36	
cancer and anti-inflammatory therapeutic approaches through manipulation of 37	
autophagy for cancer treatment regimes or conversely tagging cancer cells for 38	
destruction through proteasome or autophagy up-regulation (304).  39	
 40	
5.2. Rheumatoid Arthritis  41	
Chronic tissue inflammation has an important role in the aetiology and 42	
immunopathogenesis of rheumatoid arthritis (RA) (305), with genetic and 43	
environmental factors contributing to a predilection to develop the disease. In the pre-44	
clinical asymptomatic phase of RA disease, the immune system is characterized by 45	
reduced self-tolerance and production of autoantibodies, whereas in the clinical phase 46	
(306) innate and adaptive immune cells infiltrate the synovial joints and produce 47	
symptoms of joint pain and stiffness (307,308). As RA progresses, immune cells and 48	
synovial fibroblasts, produce a pro-inflammatory environment in the joint (309,310) 49	
leading to joint destruction (305). Cell-specific cytokines include TNF-α, IL-1 and 50	
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IL-6 from macrophages, IL-6, IL-7 and IL-15 from memory T-cells, IL-1 and IL-17 1	
from helper T-cells, and IL-1, IL-6, IL-18, GM-CSF and TGF-β from synovial 2	
fibroblasts (306,311). This complex cytokine milieu attracts further immune cells, 3	
promotes abnormal angiogenesis and osteoclastogenesis, poorly formed and leaky 4	
vasculature and leads to systemic effects (312). 5	
 6	
There is evidence to suggest that activation of the NLRP3-inflammasome contributes 7	
to the inflammatory processes in rheumatoid arthritis. Active RA subjects have 8	
increased expression of NLRP3 and NLRP3 –mediated IL-18 secretion in whole 9	
blood upon stimulation via TLR3 and TLR4 but not TLR2 receptors (313,314). 10	
Functional polymorphisms in the genes coding for NLRP3 and its component parts, 11	
including CARD8 has been shown to contribute to higher disease activity at diagnosis 12	
and for response in the early months of treatment. (315,316). 13	
 14	
Patients with rheumatoid arthritis show premature immune aging and accumulation of 15	
CD28- pre-aged effector T cells that associate with disease activation and prognosis 16	
(317,318). A novel T-cell subset-CD28- Treg-like cells has been described that 17	
produce pro-inflammatory cytokines, mirroring the SASP associated with senescent 18	
cells (319). Rheumatoid arthritis patients who show CD28- senescent Treg-like cells  19	
in blood seem to demonstrate earlier and more severe osteoporosis.(320). 20	
 21	
Limiting inflammation before damage occurs is central to successful RA management 22	
and the use of specific monoclonal antibodies has been a key therapeutic strategy. The 23	
central roles of TNF and IL-6 in RA have been corroborated by clinical trials of 24	
biologic drugs, which can specifically target and neutralize these cytokines. Evidence 25	
from RA clinical subgroups stratified by responses to specific biologic drugs strongly 26	
suggest that for a particular individual, inflammation is coordinated by a predominant 27	
cytokine pathway, such as TNF or IL-6 (321). 28	
 29	
Anti-TNF biologics such as adalimumab, etanercept and infliximab reduce 30	
inflammation, pain, neovascularisation, lymphocyte infiltration and increase 31	
macrophage apoptosis (321-324). Anti-IL-6R biologics such as tociluzimab and anti-32	
IL-6 such as sirukumab, strongly reduce disease activity and erosive progression 33	
(325,326). Evidence suggests that the predominant cell cytokines seen in synovial 34	
histopathology may act as prognostic biomarkers for stratification of RA patients 35	
(327-329). 36	
 37	
Studies of TNF and IL-6 gene polymorphisms further support their role in RA risk 38	
and severity. SNPs in IL-6 and IL-6R genes associate with increased RA risk and 39	
joint damage (330-332) and the TNF 308G gene polymorphism with RA disease 40	
severity and poor response to anti-TNF treatment (333-337). In the elderly person 41	
with RA, there is difficulty in distinguishing whether chronic inflammation or genetic 42	
‘predisposition’ initiates disease or if late-onset RA is hastened by the pro-43	
inflammatory phenotype associated with aging. Tumor necrosis factor α (TNF-α) 44	
inhibitors used as disease-modifying agents in RA improve not only the clinical 45	
symptoms of rheumatoid arthritis but decrease the associated vascular risk (338), 46	
suggesting that a stratified biologic approach may be of use to therapeutically dampen 47	
chronic systemic inflammation related to aging and other age-related diseases.  48	
 49	
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Like other age-related diseases and aging itself, there is evidence for dysregulation in 1	
both the autophagy-lysosomal and the ubiquitin-proteasomal systems in rheumatoid 2	
arthritis (339). Autophagy seems to be activated in RA in a TNFα-dependent manner 3	
and regulates osteoclast differentiation and bone resorption, emphasising a central 4	
role for autophagy in joint destruction (340). Gene and allele frequency population 5	
differences seem also to contribute to the how effectively cellular autophagy 6	
processes work within the cell in removing damaged proteins and other necrotic 7	
cellular debris. Polymorphisms of the ubiquitn E3 ligase gene that directly affects of 8	
autophagy have also been identified and have been associated with the aetiology and 9	
response to drug treatment in RA (341,342). Both are likely important contributors to 10	
the action and effectiveness of disease modifying and monoclonal biological drugs 11	
used in RA treatment. The role of the NLPR3 inflammasome may give opportunities 12	
for developing other disease modifying drugs by targeting upstream triggers of the 13	
NLPR3 pathway.  14	
 15	
5.3. Atherosclerosis  16	
Atherosclerosis is recognized as a chronic inflammatory condition (343) and 17	
atherosclerotic plaques show cellular senescence (344,345). Cytokines are involved in 18	
all stages of the pathogenesis of atherosclerosis, having both pro- or anti-atherogenic 19	
effects (346,347). In response to increased low-density lipoprotein (LDL), 20	
hypertension and subsequent shear stress, cytokines modulate endothelial cell 21	
permeability and recruit monocytes and T-lymphocytes (348,349). The continuous 22	
monocyte recruitment, foam cell and fatty steak formation eventually result in 23	
unstable plaque development, thrombosis and a cardiac event (349,350).  24	
 25	
Chronic unresolved inflammation is a key feature in atherosclerosis and the levels of 26	
SPMs, particularly resolvin D1 (RvD1), and the ratio of SPMs to pro-inflammatory 27	
leukotriene B4 (LTB4), are significantly decreased in the vulnerable plaque regions 28	
(27). Vulnerable atherosclerotic plaques are recognized as having distinct features; 29	
increased inflammation; oxidative stress; areas of necrosis overlain by a thin 30	
protective layer of collagen (fibrous cap). In advanced atherosclerotic plaques, 31	
macrophages have more abundant nuclear 5-lipoxygenase (5- LOX), which is 32	
suggested to lead to conversion of arachidonic acid to proinflammatory leukotrienes, 33	
with the potential to contribute to plaque rupture (27).  34	
 35	
The NLRP3 inflammasome, a central regulator of inflammation (58), is activated by 36	
cholesterol crystals and oxidized LDL (351,352) that drives the IL-1β inflammation 37	
pathway. Recent research targeting IL-1β inflammation in atherosclerosis using 38	
cannakinumab, a therapeutic monoclonal antibody, has shown up to fifteen percent 39	
lower rates of recurrent cardiovascular events, which was independent of lipid 40	
lowering (353). As well as playing a major role in chronic inflammation, NLRP3 is 41	
also upregulated during endothelial cell senescence (354) via ROS, and is negatively 42	
regulated by autophagy (355,356). The NLRP3 inflammasome therefore appears to 43	
warrant further investigation as a potential target for inflamm-aging related to 44	
atherosclerosis given that such mechanisms are now of well known importance in 45	
atherosclerosis (357).  46	
 47	
The gut microbiome has been implicated in age-related inflammation (358) with 48	
numerous studies reporting bacterial organisms in arterial plaque (359-361). 49	
Emerging research reports bacterial DNA in blood associated to a personal microbiota 50	
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fingerprint as a predictor of cardiovascular events and stool microbiome as a signature 1	
of cardiovascular disease (362,363). Similarly bacterial DNA has been noted in cell-2	
free plasma in cardiovascular and chronic renal disease patients (364,365). Altered gut 3	
microbiota composition or dysbiosis is also seen in elderly people, and is associated 4	
with inflammatory markers (358). Aging leads to changes in intestinal permeability in 5	
gut bacterial milieu (366) and the increased circulatory bacterial DNA observed 6	
associated with atherosclerosis support further investigation of the microbiome as a 7	
contributory factor to age-related inflammation and atherosclerosis.  8	
 9	
5.4. Neuroinflammation and neurodegenerative disease  10	
Inflammation has been well established as a major component of neurodegenerative 11	
disorders, but it has never been clear if this was a direct cause of the disease or a 12	
consequence of the progressive degenerative process that was occurring (367,368). 13	
The central role of cytokines in regulating the immune response has been implicated 14	
in neurodegeneration, but over the last decade, there has been a revolution in our 15	
understanding of how cytokines contribute to the aetiology of the leading 16	
neurodegenerative disorders, including Alzheimer’s (AD) and Parkinson’s disease 17	
(PD).  18	
 19	
In AD, central events seem to include the inflammasome, the NF-κB pathway and 20	
activation of microglia by a variety of factors including beta amyloid and pro-21	
inflammatory cytokines (174). Microglia, the primary components of the CNS innate 22	
immune system (369), produce cytokines and monitor the integrity of CNS. Together 23	
with astrocytes, microglia are the primary effectors of neuroinflammation and express 24	
PPRs that allow early recognition of PAMPs and DAMPs. When the NLRP3 25	
inflammasome is activated, the inflammation cascade begins with caspase-1 that 26	
facilitates the processing of IL-1β and IL18. These proinflammatory cytokines drive 27	
the inflammatory cascade through downstream signalling pathways and lead to 28	
neuronal damage and death (370). The activated microglia release proinflammatory 29	
ctyokines such as IL-1β, IL-6, TNF-α and IL-18, that contributes to neuronal death 30	
and dysfunction.  31	
 32	
There is interest in the role of sphingolipid metabolites such as ceramide and 33	
sphingosine-1-phosphate that regulate a diverse range of cellular processes that are 34	
important in immunity, inflammation and inflammatory diseases (371). Growing 35	
evidence suggests that ceramide may play a critical role in NLRP3 inflammasome 36	
assembly in neuroinflammation. Research has shown that microglia treated with 37	
sodium palmitate (PA) induce de novo ceramide synthesis, triggering the expression 38	
of NLRP3 inflammasome assembly and resulting in release of IL-1β (372), linking 39	
neuroinflammation with dietary lipids. Recent insights into the molecular mechanisms 40	
of action of sphingolipid metabolites suggest roles in altering membrane composition, 41	
with effects on cellular interactions and signaling pathways with potential causal 42	
relationships to neuroinflammatory disease. 43	
 44	
Dysregulated autophagy has been considered to play a role in neurodegenerative 45	
diseases, particularly AD, and is felt to be a key regulator of Aβ abnormal protein 46	
generation and clearance (373). In AD the maturation of autophagolysosomes (i.e., 47	
autophagosomes that have undergone fusion with lysosomes) and their clearance are 48	
hindered. Evidence suggests that Aβ peptides are released from neurons in an 49	
autophagy-dependent manner and that the accumulation of intracellular Aβ plaques is 50	
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toxic to brain cells leading to AD pathology (374). Furthermore lysosomal and 1	
autophagocytic dysfunction has been associated with both Alzheimer’s and 2	
Parkinson’s diseases (72,71). Senescent cells too, accumulate abnormal protein 3	
aggregates in the cytoplasm that contribute to neurodegenerative disease (72). 4	
Cellular senescence has been reported in the aging brain with an increase in SASP-5	
expressing senescent cells of non-neurological origin that are likely to contribute to 6	
the pro-inflammatory background (105,375).  7	
 8	
In AD and PD the application of genome-wide association studies (GWAS) have 9	
demonstrated a number of key genes, relating to immunity, including the Human 10	
Leukocyte Antigen (HLA) complex on chromosome 6 that regulates the immune and 11	
inflammatory response (376,377). In the most recent Parkinson’s disease GWAS a 12	
locus containing the IL-1R2 gene was identified as significantly associated with 13	
disease risk and awaits further investigation (376). There is some evidence that 14	
carriage of certain pro-inflammatory cytokine gene alleles may confer increased 15	
Alzheimer’s disease risk. Single studies have reported that carriers of the A allele of 16	
the TNF-α 308 G/A gene were variably associated with increased risk of Alzheimer’s 17	
disease (209-212) and that carriage the higher IL-6 producing allele of IL-6 (174G/C) 18	
may confer increased risk (188,192,193). Animal studies have provided some clearer 19	
understanding of the role of TNF-α in Alzheimer’s disease with evidence of disease 20	
modulation with the use of anti-TNF agents (217). Three studies, published in 2013, 21	
confirmed a role for the immune response in AD identifying the microglia-related 22	
gene TREM2 as harboring an intermediate effect size variant in risk of AD that has 23	
also been implicated in other related neurodegenerative diseases (378-380). A recent 24	
study of rare variants has also implicated a role for microglial-mediated innate 25	
immunity in AD (381). 26	
 27	
A better understanding of the molecular pathways involved in the use of established 28	
drugs such as non-steroidal anti-inflammatory or statin drugs in risk and progression 29	
of neurological disorders may provide further opportunities to treat earlier or prevent 30	
disease onset (382-384). It has been considered that down-regulation of the type and 31	
magnitude of the pro-inflammatory immune response in neurodegeneration might be 32	
a key to earlier and more successful targeting of these pathways. However results, to 33	
date, have been disappointing and anti-TNF-a therapies and targeted treatment of 34	
TNF-a levels that are elevated in cerebrospinal fluid and in patients’ serum, have 35	
produced, at best, modest results (385). Multiple sclerosis patients have benefited 36	
from treatment with fingolimod (FTY720) that has been reported to attenuate 37	
neuroinflammation, by regulating the activation and neuroprotective effects of 38	
microglia, by modulating the sphingosine-1-phosphate receptor (S1P receptor) (386). 39	
Given the success of FTY720 for treatment of multiple sclerosis, it is hoped that next-40	
generation S1PR1 modulators will find wider therapeutic uses in other inflammatory 41	
disorders. Fingolimod is now under a phase 2 clinical trials for acute stroke and phase 42	
4 for neurodegeneration (387).  43	
 44	
6. Future Considerations  45	
Aging is heterogeneous amongst people and highly variable between different organs 46	
and tissues. Our genes, our lifestyles and our response to stress are infinitely 47	
individual and variable, so that the immunobiography of each life tells a different 48	
story of how each will respond to the internal and external environmental stressors (1-49	
3, 388). But evidence is accumulating that the aging process may be malleable. 50	
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 1	
Because aging is the major risk factor for age-related diseases, understanding how to 2	
age better and maintaining the health of older people and societies is highly important 3	
personally and for societies and governments. Knowledge about the underlying 4	
molecular pathways and the genetic and life-style processes associated with age-5	
related disease and aging itself is increasing. Evidence from centenarian and 6	
nonagenarian studies suggests that these oldest members of populations have had the 7	
ability to delay aging and age-related disease (389,390). Other studies suggest that 8	
centenarians may demonstrate optimized cardiovascular risk factors (391,392), or 9	
have either intuitively or through social example, adopted lifestyles which have 10	
interacted with their genes to facilitate a successful aging phenotype (3,393,394).  11	
 12	
Population studies across the world show that the age-specific incidence of 13	
cardiovascular disease, stroke and dementia is decreasing (395-399). This suggests 14	
that better blood pressure and diabetic control and statin use may directly or indirectly 15	
link into, and down-regulate molecular pathways associated with inflammation (400-16	
403). Research into how carriage of certain gene alleles, such as TCF7L2 or IL-6 can 17	
increase inflammation or stroke risk respectively, and can be ameliorated by 18	
following a Mediterranean-type diet (42, 404,405), or how gene splicing and features 19	
of senescence may be modulated by resveratrol in food (406), herald research into 20	
how gene, diet and life-styles can interact, with positive or negative effects on the 21	
immune system and health. Increased knowledge is emerging as to how epigenetic 22	
modulation can affect cytokine genes with reports linking cytokine epigenetic change 23	
to neuroinflammation (407-409). Obesity, smoking and malnutrition have been shown 24	
to have next generational epigenetic effects, and seem likely to contribute to the 25	
predilection of offspring developing age-related disease or conversely the longevity 26	
phenotype (410-413).  27	
 28	
Other strategies should be adopted which link with public health messages and 29	
encourage people to adopt behavioural changes in life-styles. Modifications should 30	
include: changes in diets to include more omega-3 containing foods or fruits and 31	
vegetables as in the Mediterranean diet (414-417); engagement in regular moderated 32	
exercise routines (418-421); continued engagement with social connections and 33	
intellectual activities in daily lives (422-424); or best of all a combination of life-style 34	
factors (3,425,426), all of which have been shown to reduce the inflammatory profile 35	
and improve the quality of aging. Although the role of diet on human health and 36	
connections through nutrition, inflammation and cancer are not as linear as those 37	
between tobacco, smoking and lung cancer, obesity is linked to chronic inflammation 38	
through several mechanisms including the dysregulation of autophagy, whereas 39	
fasting has anti-inflammatory effects, similar to the effect of exercise (427-430), and 40	
may down-regulate inflammatory biomarkers (431-433). There is therefore 41	
considerable interest in the role of the intestinal microbiota and health and the so-42	
called immune-relevant microbiome (358) 327), with important correlations between 43	
inflammation and neurodegenerative disease, (434-436), bacterial β-hydroxybutyrate 44	
metabolites (427), and the role of vagal stimulation (428).  45	
 46	
Increasing evidence shows that many signalling pathways are activated in a stress-47	
type-dependent fashion, and all appear to converge with nuclear factor (NF)-κB 48	
signalling, which is a central controller of the immune response, and inflammatory 49	
cascade (439-443). With increasing age immune homeostasis loosens, NF-kB 50	
In r v
ew
	 26	
signalling becomes less tightly controlled or is more readily triggered, cytokine 1	
dysregulation occurs and a pro-inflammatory phenotype predominates that underpins 2	
most major age-related diseases from atherosclerosis to cancer, and aging itself 3	
(Figure 5). Understanding how different factors trigger the NF-κB cascade is an 4	
important pathway of research (440). In animal models, miRNA-based regulatory 5	
networks involving miR -155 and miR-146a, finely regulate NF-κB activity, with 6	
miR-146a down-regulating and miR-155 upregulating NF-κB expression (441). There 7	
is an important temporal separation of miR -155 and miR-146a cellular expression 8	
that allows finely controlled NK-κB signalling and enables a precise macrophage 9	
inflammatory response, which merits further research.  10	
 11	
Therapeutic opportunities may arise through better understanding of the molecular 12	
mechanisms that induce senescent cells and SASP in the cellular environments of 13	
chronic disease or whether senescent cells can be removed by up-regulating 14	
autophagy and using sophisticated tagging mechanisms (442). There will be increased 15	
opportunities to use the knowledge gained from clinical studies in auto-immune 16	
disease, about the roles and actions of monoclonal antibodies in modulating 17	
inflammation, which may be able to be utilized in treatments for other age-related 18	
diseases involving inflammation (443). The formulations of new and more specific 19	
drugs are likely to become available as the modes of action of kinases such a AMPK 20	
and m-TOR which control the senescence and inflammation pathways, become better 21	
understood (444-446). Old drugs such as metformin, still used in diabetes control, are 22	
being repurposed and have been shown to have exciting new uses through their ability 23	
to modify epigenetic gene expression. Clinical studies are underway to assess any 24	
modulating effect of metformin in aging and age-related diseases (445). The use of 25	
histone deacetylating drugs is likely to increase as the clinical use of deacetylation 26	
and methylation agents is evaluated in cancer with improved knowledge of their 27	
effects and safety criteria (447). The current interest in diet and modified diets will 28	
encourage further studies assessing how nutrachemicals modify gene expression, for 29	
example, through the regulation of intracellular receptors that bind the promoters of 30	
certain genes, and may help design more specific drugs to modify metabolism and 31	
benefit health (448).  32	
 33	
Turning research to focus on improved understanding of the mechanisms of 34	
inflammation resolution in aging and age-related disease, should also be prioritised 35	
since it is an under researched area. Developing synthetic resolvins for use in 36	
inflammation resolution may have advantages over the use of single biological anti-37	
inflammatory blockers in auto-immune disease clinical management, since cytokine 38	
networks are highly interactive and complex (449), with many auto-regulatory 39	
feedback loops. All these molecular pathways are, or have the potential for being 40	
developed as drug targets towards clinical interventions useful in damping down and 41	
modulating inflammation (450,451) and may have a role in delaying the onset or 42	
treatment of age-related diseases. 43	
 44	
Evidence from on-going global studies of the oldest members of our societies such as 45	
centenarians and nonagenarians (452-463) suggests that it may be possible to delay 46	
age-related diseases and that aging may be a potentially modifiable risk factor (464). 47	
Further investigation has shown that centenarians and super-centenarians also have an 48	
enhanced pro-inflammatory background (465-467), which at first seems surprising, 49	
given their long lives. However, studies have demonstrated that the pro-inflammatory 50	
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background is accompanied and perhaps modulated, by an enhanced anti-1	
inflammatory status in some centenarians. Some have argued that an enhanced anti-2	
inflammatory phenotype could be beneficial as a contributor to longevity by 3	
effectively controlling the pro-inflammatory background (9,11,260). Others suggest 4	
that some inflammation is good, in the same way as hormetic stress triggers systems, 5	
and upgrades them but does not overwhelm them (468). Regular exposure to pro-6	
inflammatory stressors could train the immune system to up-regulate and fine-tune its 7	
cellular processes, so that it responds better and provides better outcomes, when faced 8	
with real life-threatening pathogenic threats.   9	
 10	
GWAS have proved a powerful methodology to assess the influence of common 11	
variation in AD and PD disease susceptibility, but by their nature have reflected low 12	
effect size variants that likely have a cumulative effect on risk (469). As Next-13	
Generation sequencing technology becomes more cost-effective, the ability to identify 14	
variants that are less common (<1% minor allele frequency) will become more 15	
achievable. These unbiased approaches should aid the identification of key players in 16	
the inflamm-aging pathway and will play a critical role in the development of 17	
therapeutic intervention strategies in neurodegenerative and age-related diseases.  18	
 19	
There is the increasing opportunity to link large global datasets with the technologies 20	
of genomics, transcriptomics and proteomics through bioinformatics and artificial 21	
intelligence methods to unlock the physiological, genetic and molecular pathways that 22	
underpin the pro-inflammatory aging-phenotype. Using systems biology methods has 23	
the potential to lead to the generation of novel therapeutic approaches for old diseases 24	
and modern health challenges. Improving knowledge about how to delay or modify 25	
the pro-inflammatory ageing-phenotype, the hallmark of ageing and age-related 26	
disease, will give hope of a better quality aging and the longevity dividend for all.  27	
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 1	
Figure 1 Inflammation Pathway to Resolution 2	
 3	
 4	
 5	
 6	
An illustration of the sequence of key processes (in capitalised text), cells and 7	
molecules involved in reaction to injury or infection, and how the inflammatory 8	
episode is resolved over time (from left to right). Cells from the innate and adaptive 9	
immune system that are involved in cell recruitment, phagocytosis and clearance 10	
processes are highlighted in blue text; key molecules are in italic text. 11	
 12	
 13	
 14	
 15	
 16	
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Figure 2 The Arachidonic Acid Pathway of Inflammation 1	
Mediators 2	
 3	
 4	
 5	
 6	
In the simplified pathway for the eicosanoid metabolic pathway, arachidonic acid 7	
(AA) is released from membrane stores by phospholipase 2 (PLA2). Arachidonic acid 8	
is metabolised to biological mediators by three enzymatic pathways: cyclooxygenase 9	
(COX), lipoxygenase (LOX), and cytochrome P450 (CYTP). Each pathway contains 10	
enzyme-specific steps that result in a wide variety of bioactive compounds that drive 11	
the pro-inflammatory (prostaglandins) response. After lipid mediator class switching 12	
at the height of inflammation the pro-resolving mediators-lipoxins begin to drive 13	
inflammation resolution. Eicosapentanenoic acid (EPA) and docosahexanenoic acid 14	
(DHA) derived from dietary sources produce the E-series of resolvins and D-series of 15	
resolvins, maresins and protectins respectively, which are important pro-resolving 16	
mediators in progressing the resolution of inflammation.  17	
 18	
 19	
 20	
 21	
 22	
 23	
 24	
 25	
 26	
 27	
 28	
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Figure 3a The Ubiquitin Proteasome Pathway of Protein 1	
Degradation  2	
 3	
 4	
Three different sets of enzymes -E1, E2, and E3, identify and categorise proteins in 5	
order to link ubiquitin (ub) or ubiquitin complexes to the damaged proteins. The 6	
ubiquitin-protein complexes pass through the proteasome where they are degraded 7	
and discharged as free amino acids into the cytoplasm.	8	 	9	
Figure	3b	 The	Autophagy	Pathway	of	Degradation	of	Damaged	10	
Organelles	and	Pathogens		11	 	12	
	13	
The autophagy system degrades larger aggregated proteins and cellular organelles 14	
such as mitochondria, peroxisomes and infectious organisms. The process involves 15	
membrane formation, fusion and degradation. A small separate membrane called a 16	
phagophore forms and then forms the autophagosome that fuses with the lysosome. 17	
The autophagosome contents are degraded by lysosomal hydrolases.	18	
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Figure 4 Mitochondrial ROS and NLRP3 Activation of 1	
Inflammation Pathway 2	 	3	
	4	
Mitochondrial reactive oxygen species (ROS) from damaged mitochondria triggers 5	
the inflammasome NLRP3, stimulating NF-κB and the IL-1β-and IL-18 mediated 6	
inflammatory cascade. The adapter protein ASC mediates innate signaling by 7	
bridging the interaction between the damage recognition receptor (DAMP) and the 8	
NF-κB caspase-1-inflammasome complex.  9	 	10	 	11	 	12	 	13	 	14	 	15	 	16	 	17	 	18	 	19	 	20	 	21	 	22	 	23	 	24	 	25	 	26	 	27	
	28	
I  r vi
ew
	 73	
Figure	5	 Cytokine Dysregulation and NF-κB Inflammation 1	
Pathway  2	 	3	 	4	
	5	 	6	
This reshaping of cytokine expression pattern, with a progressive tendency toward a 7	
pro-inflammatory phenotype has been called ‘inflamm-aging’ and is found associated 8	
with age-related diseases. Several molecular pathways have been identified that 9	
trigger the inflammasome and stimulate the NF-κB and the IL-1β-mediated 10	
inflammatory cascade of cytokines. 	11	 	12	
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